Avacta Group PLC Notice of Results (7719Z)
September 05 2018 - 2:01AM
UK Regulatory
TIDMAVCT
RNS Number : 7719Z
Avacta Group PLC
05 September 2018
5 September 2018
Avacta Group plc
("Avacta", the "Group" or the "Company")
Notice of Results
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and reagents, will announce its financial results
for the year ended 31 July 2018 on Tuesday, 2 October 2018.
An analyst briefing given by Alastair Smith, Chief Executive
Officer and Tony Gardiner, Chief Financial Officer, will be held at
09.30 hrs on Tuesday, 2 October 2018 at finnCap's offices, 60 New
Broad St, London EC2M 1JJ.
- Ends -
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414 0452
Alastair Smith, Chief Executive Officer www.avacta.com
Tony Gardiner, Chief Financial Officer
finnCap Ltd Tel: +44 (0) 207 220 0500
Geoff Nash / Giles Rolls - Nominated www.finncap.com
Adviser
Tim Redfern / Nikita Jain - Corporate
Broking Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9317
WG Partners www.wgpartners.co.uk
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang
Zyme Communications (Trade and Regional Tel: +44 (0)7787 502 947
Media) katie.odgaard@zymecommunications.com
Katie Odgaard
Tel: +44 (0)7764 947137
Yellow Jersey (Financial Media and avacta@yellowjerseypr.com
IR)
Sarah Hollins
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORSSEESLFASESU
(END) Dow Jones Newswires
September 05, 2018 02:01 ET (06:01 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024